Larix laricina, an Antidiabetic Alternative Treatment from the Cree of Northern Quebec Pharmacopoeia, Decreases Glycemia and Improves Insulin Sensitivity In Vivo
Figure 1
Area under the curve (AUC) of nonfasting glycemia levels, in C57BL/6 mice treated with either HFD (DIO) or L. laricina at 125 or 250 mg/kg, which was incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. Total AUC for blood glucose levels versus time (a) was calculated and then fractionated into the first and second half of the feeding period corresponding to weeks 0–4 (AUCF1; b) and weeks 4–8 (AUCF2; c), respectively. All values are mean ± SEM. Number of animals/group for prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8). *denotes significantly different as compared to DIO group (one-way ANOVA; post hoc analysis Holm-Sidak or Bonferroni-Dunn test; ).
